JP2017525699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525699A5 JP2017525699A5 JP2017508531A JP2017508531A JP2017525699A5 JP 2017525699 A5 JP2017525699 A5 JP 2017525699A5 JP 2017508531 A JP2017508531 A JP 2017508531A JP 2017508531 A JP2017508531 A JP 2017508531A JP 2017525699 A5 JP2017525699 A5 JP 2017525699A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- alkyl
- acceptable salt
- formula
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 101
- 150000001875 compounds Chemical class 0.000 claims description 96
- 125000000217 alkyl group Chemical group 0.000 claims description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims description 51
- 229910052799 carbon Inorganic materials 0.000 claims description 48
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 28
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 21
- 150000002148 esters Chemical class 0.000 claims description 20
- 125000003003 spiro group Chemical group 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 19
- 125000006413 ring segment Chemical group 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 17
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 16
- 229910052731 fluorine Inorganic materials 0.000 claims description 15
- 150000001721 carbon Chemical group 0.000 claims description 14
- 241000282412 Homo Species 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 11
- 241000711904 Pneumoviridae Species 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 8
- 229920002554 vinyl polymer Polymers 0.000 claims description 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 6
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 4
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 4
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 229910019946 S-S Inorganic materials 0.000 claims description 2
- 229910019939 S—S Inorganic materials 0.000 claims description 2
- 230000002730 additional effect Effects 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 17
- 229940126062 Compound A Drugs 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040349P | 2014-08-21 | 2014-08-21 | |
| US62/040,349 | 2014-08-21 | ||
| PCT/US2015/045849 WO2016028866A1 (en) | 2014-08-21 | 2015-08-19 | 2'-chloro aminopyrimidinone and pyrimidine dione nucleosides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020070958A Division JP2020111608A (ja) | 2014-08-21 | 2020-04-10 | ２’−クロロアミノピリミジノンおよびピリミジンジオンヌクレオシド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525699A JP2017525699A (ja) | 2017-09-07 |
| JP2017525699A5 true JP2017525699A5 (OSRAM) | 2018-09-06 |
| JP6765364B2 JP6765364B2 (ja) | 2020-10-07 |
Family
ID=54066190
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017508531A Active JP6765364B2 (ja) | 2014-08-21 | 2015-08-19 | ２’−クロロアミノピリミジノンおよびピリミジンジオンヌクレオシド |
| JP2020070958A Withdrawn JP2020111608A (ja) | 2014-08-21 | 2020-04-10 | ２’−クロロアミノピリミジノンおよびピリミジンジオンヌクレオシド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020070958A Withdrawn JP2020111608A (ja) | 2014-08-21 | 2020-04-10 | ２’−クロロアミノピリミジノンおよびピリミジンジオンヌクレオシド |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US9617295B2 (OSRAM) |
| EP (2) | EP3183261B1 (OSRAM) |
| JP (2) | JP6765364B2 (OSRAM) |
| KR (1) | KR102528928B1 (OSRAM) |
| CN (1) | CN106573954A (OSRAM) |
| AR (1) | AR101561A1 (OSRAM) |
| AU (1) | AU2015305593C1 (OSRAM) |
| BR (1) | BR112017003242A2 (OSRAM) |
| CA (1) | CA2958546C (OSRAM) |
| EA (1) | EA201790234A1 (OSRAM) |
| ES (1) | ES2808868T3 (OSRAM) |
| IL (1) | IL250426A0 (OSRAM) |
| MX (1) | MX2017002288A (OSRAM) |
| NZ (1) | NZ728707A (OSRAM) |
| SG (1) | SG11201700810SA (OSRAM) |
| TW (1) | TWI673283B (OSRAM) |
| WO (1) | WO2016028866A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2794627T3 (pl) | 2011-12-22 | 2019-04-30 | Alios Biopharma Inc | Podstawione nukleozydy, nukleotydy i ich analogi |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| TWI673283B (zh) * | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | ２’－氯胺基嘧啶酮及嘧啶二酮核苷類 |
| JP6671355B2 (ja) * | 2014-09-26 | 2020-03-25 | リボサイエンス・エルエルシー | 呼吸器多核体ウイルスのｒｎａ複製の阻害剤としての４’‐ビニル置換ヌクレオシド誘導体 |
| SMT202100592T1 (it) | 2014-12-26 | 2021-11-12 | Univ Emory | Derivati antivirali della n4-idrossicitidina |
| WO2018009623A1 (en) * | 2016-07-08 | 2018-01-11 | Atea Pharmaceuticals, Inc. | β-D-2'-DEOXY-2'-SUBSTITUTED-4'-SUBSTITUTED-2-SUBSTITUTED-N6-SUBSTITUTED-6-AMINOPURINE NUCLEOTIDES FOR THE TREATMENT OF PARAMYXOVIRUS AND ORTHOMYXOVIRUS INFECTIONS |
| KR20240011880A (ko) | 2017-12-07 | 2024-01-26 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| EP4431100A4 (en) * | 2021-11-12 | 2025-01-15 | National University Corporation Hokkaido University | ANTIVIRAL AGENT |
| CA3245459A1 (en) | 2022-03-15 | 2023-09-21 | Rome Therapeutics, Inc. | COMPOUNDS AND METHODS FOR TREATING A DISEASE |
| WO2024016639A1 (zh) * | 2022-07-21 | 2024-01-25 | 华创合成制药股份有限公司 | 一种抗病毒感染的化合物及其制备方法和用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
| US3565070A (en) | 1969-02-28 | 1971-02-23 | Riker Laboratories Inc | Inhalation actuable aerosol dispenser |
| FR2224175B1 (OSRAM) | 1973-04-04 | 1978-04-14 | Isf Spa | |
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| IT1017153B (it) | 1974-07-15 | 1977-07-20 | Isf Spa | Apparecchio per inalazioni |
| SE438261B (sv) | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
| US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US4955371A (en) | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
| AU662919B2 (en) | 1991-07-02 | 1995-09-21 | Inhale, Inc. | Method and device for delivering aerosolized medicaments |
| US5261538A (en) | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US5388572A (en) | 1993-10-26 | 1995-02-14 | Tenax Corporation (A Connecticut Corp.) | Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5622163A (en) | 1994-11-29 | 1997-04-22 | Iep Group, Inc. | Counter for fluid dispensers |
| US5544647A (en) | 1994-11-29 | 1996-08-13 | Iep Group, Inc. | Metered dose inhalator |
| US6116234A (en) | 1999-02-01 | 2000-09-12 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler agitator |
| KR20040028657A (ko) * | 2000-10-18 | 2004-04-03 | 파마셋, 리미티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드 |
| WO2008089105A2 (en) | 2007-01-12 | 2008-07-24 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| EP2155758B1 (en) | 2007-05-10 | 2012-08-22 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro[3,4-d]dioxolane compounds for use in the treatment of viral infections and cancer |
| DK2268642T3 (en) | 2008-04-23 | 2015-05-26 | Gilead Sciences Inc | 1'-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT |
| WO2010002877A2 (en) | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| CA2773773C (en) | 2009-09-21 | 2019-04-23 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
| US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| EP2480552B1 (en) | 2009-09-21 | 2016-11-09 | Gilead Sciences, Inc. | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| US9090642B2 (en) | 2010-07-19 | 2015-07-28 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| SI2595980T1 (sl) | 2010-07-22 | 2014-11-28 | Gilead Sciences, Inc. | Postopki in sestavki za zdravljenje paramyxoviridae virusnih infekcij |
| TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之２’－氟取代之碳－核苷類似物 |
| ES2701020T3 (es) * | 2010-09-22 | 2019-02-20 | Alios Biopharma Inc | Nucleósidos azido y análogos nucleotídicos |
| US20130273005A1 (en) | 2010-12-20 | 2013-10-17 | Gilead Sciences, Inc. | Methods for treating hcv |
| WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| PL2794627T3 (pl) * | 2011-12-22 | 2019-04-30 | Alios Biopharma Inc | Podstawione nukleozydy, nukleotydy i ich analogi |
| JP6430364B2 (ja) * | 2012-03-21 | 2018-11-28 | アリオス バイオファーマ インク． | 置換されたヌクレオシド、ヌクレオチドおよびそのアナログ |
| GB201220843D0 (en) * | 2012-11-20 | 2013-01-02 | Univ College Cork Nat Univ Ie | Compound |
| US10034893B2 (en) * | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
| EP3013340B9 (en) * | 2013-06-26 | 2023-10-04 | Janssen Pharmaceuticals, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| JP6562908B2 (ja) * | 2013-10-11 | 2019-08-21 | ヤンセン バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびその類似体 |
| TWI673283B (zh) * | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | ２’－氯胺基嘧啶酮及嘧啶二酮核苷類 |
-
2015
- 2015-08-07 TW TW104125796A patent/TWI673283B/zh active
- 2015-08-14 AR ARP150102625A patent/AR101561A1/es unknown
- 2015-08-19 EP EP15760544.5A patent/EP3183261B1/en active Active
- 2015-08-19 AU AU2015305593A patent/AU2015305593C1/en active Active
- 2015-08-19 EP EP20180058.8A patent/EP3738969A1/en active Pending
- 2015-08-19 WO PCT/US2015/045849 patent/WO2016028866A1/en not_active Ceased
- 2015-08-19 MX MX2017002288A patent/MX2017002288A/es unknown
- 2015-08-19 CA CA2958546A patent/CA2958546C/en active Active
- 2015-08-19 EA EA201790234A patent/EA201790234A1/ru unknown
- 2015-08-19 KR KR1020177006312A patent/KR102528928B1/ko active Active
- 2015-08-19 ES ES15760544T patent/ES2808868T3/es active Active
- 2015-08-19 US US14/830,121 patent/US9617295B2/en active Active
- 2015-08-19 JP JP2017508531A patent/JP6765364B2/ja active Active
- 2015-08-19 NZ NZ728707A patent/NZ728707A/en unknown
- 2015-08-19 BR BR112017003242A patent/BR112017003242A2/pt not_active Application Discontinuation
- 2015-08-19 SG SG11201700810SA patent/SG11201700810SA/en unknown
- 2015-08-19 CN CN201580044979.5A patent/CN106573954A/zh active Pending
-
2017
- 2017-02-02 IL IL250426A patent/IL250426A0/en unknown
- 2017-02-24 US US15/441,561 patent/US9982006B2/en active Active
-
2018
- 2018-04-11 US US15/950,442 patent/US20180340004A1/en not_active Abandoned
- 2018-12-06 US US16/212,374 patent/US20190202852A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,536 patent/US20200157137A1/en not_active Abandoned
- 2019-09-10 US US16/565,888 patent/US20200087337A1/en not_active Abandoned
-
2020
- 2020-04-10 JP JP2020070958A patent/JP2020111608A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525699A5 (OSRAM) | ||
| JP2017523169A5 (OSRAM) | ||
| JP2014511892A5 (OSRAM) | ||
| JP2010523522A5 (OSRAM) | ||
| JP2019529490A5 (OSRAM) | ||
| JP2013545785A5 (OSRAM) | ||
| JP2014037426A5 (OSRAM) | ||
| JP2017531038A5 (OSRAM) | ||
| JP2017537940A5 (OSRAM) | ||
| JP2015506348A5 (OSRAM) | ||
| JP2016515560A5 (OSRAM) | ||
| RU2013126041A (ru) | Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2 | |
| JP2016510038A5 (OSRAM) | ||
| JP2016518437A5 (OSRAM) | ||
| JP2019510034A5 (OSRAM) | ||
| JP2017537949A5 (OSRAM) | ||
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2014500295A5 (OSRAM) | ||
| SI2738156T1 (en) | TETRACYCLINE COMPOSITE SUBSTITUTED WITH 9-AMINOMETHYL | |
| EA202191896A1 (ru) | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2н-пиридо[1,2-]пиразин-7-карбоксамиды - ингибиторы интегразы вич, способы их получения и применения | |
| JP2013542261A5 (OSRAM) | ||
| JP2019505529A5 (OSRAM) | ||
| JP2012522766A5 (OSRAM) | ||
| JP2016540803A5 (OSRAM) |